Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Buchmann, A; Pirpamer, L; Pinter, D; Voortman, M; Helmlinger, B; Pichler, A; Maceski, AM; Benkert, P; Bachmaier, G; Ropele, S; Reindl, M; Leppert, D; Kuhle, J; Enzinger, C; Khalil, M.
High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
Eur J Neurol. 2023; 30(5):1389-1399 Doi: 10.1111/ene.15742
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Buchmann Arabella
Khalil Michael
Co-Autor*innen der Med Uni Graz
Bachmaier Gerhard
Enzinger Christian
Helmlinger Birgit
Pichler Alexander
Pinter Daniela Theresia
Pirpamer Lukas
Reindl Marco
Ropele Stefan
Voortman Margarete Maria

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

BACKGROUND AND PURPOSE: Serum neurofilament light chain (sNfL) is a promising biomarker of neuroaxonal damage in persons with multiple sclerosis (pwMS). In cross-sectional studies, sNfL has been associated with disease activity and brain magnetic resonance imaging (MRI) changes; however, it is still unclear to what extent in particular high sNfL levels impact on subsequent disease evolution. METHODS: sNfL was quantified by an ultrasensitive single molecule array (Simoa) in 199 pwMS (median age = 34.2 years, 64.3% female) and 49 controls. All pwMS underwent 3-T MRI to assess global and compartmental normalized brain volumes, T2-lesion load, and cortical mean thickness. Follow-up data and serum samples were available in 144 pwMS (median follow-up time = 3.8 years). Linear and binary logistic models were used to estimate the independent contribution of sNfL for changes in MRI and Expanded Disability Status Scale (EDSS). Age-corrected sNfL z-scores from a normative database of healthy controls were used for sensitivity analyses. RESULTS: High sNfL levels at baseline were associated with atrophy measures of the whole brain (standardized beta coefficient βj = -0.352, p < 0.001), white matter (βj = -0.229, p = 0.007), thalamus (βj = -0.372, p = 0.004), and putamen (βj = -1.687, p = 0.012). pwMS with high levels of sNfL at baseline and follow-up had a greater risk of EDSS worsening (p = 0.007). CONCLUSIONS: Already single time point elevation of sNfL has a distinct effect on brain volume changes over a short-term period, and repeated high levels of sNfL indicate accumulating physical disability. Serial assessment of sNfL may provide added value in the clinical management of pwMS.
Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Female - administration & dosage
Adult - administration & dosage
Male - administration & dosage
Multiple Sclerosis - pathology
Cross-Sectional Studies - administration & dosage
Intermediate Filaments - administration & dosage
Brain - diagnostic imaging, pathology
Central Nervous System Diseases - administration & dosage
Biomarkers - administration & dosage
Neurofilament Proteins - administration & dosage
Atrophy - pathology
Neurodegenerative Diseases - pathology

Find related publications in this database (Keywords)
multiple sclerosis
© Med Uni Graz Impressum